Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Neurol. 2021 Aug;20(8):639–652. doi: 10.1016/S1474-4422(21)00174-5

Table 2.

Adverse event summary table

Adverse Events n (%)
Total events 134
Grade 3 or higher* 21 (15·7%)
Fever 5 (3·7%)
Headache 3 (2·2%)
Hematological events 6 (4·5%)
Increased WBC 2 (1·5%)
Neutropenia 2 (1·5%)
Thrombocytopenia 2 (1·5%)
Thrombocytosis 1 (0·7%)
Anemia 1 (0·5%)
Pruritis 1 (0·5%)
Neurological worsening due to PML 25 (18·7%)
Worsening of underlying disease 10 (7·5%)
Intercurrent illness 21 (15·7%)
*

no AE grade 3 or higher deemed treatment-related